ARMS2 and age-related macular degeneration: The genetic contribution of the complement pathway (CFH, CFI, C9, C2, TMEM97/VTN, and C3 genes) and ARMS2 to AMD Stage 4 has been found to explain 90% of the overall genetic risk in a population of 17,000 patients (31).